PCA
LUCD icon

Pallas Capital Advisors’s Lucid Diagnostics LUCD Stock Holding History

Pallas Capital Advisors’s Portfolio LUCD Stock Details LUCD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$12.7K Buy
+11,874
New +$12.8K ﹤0.01% 1023

Other funds holding LUCD

Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
MCM
Masters Capital Management Atlanta, Georgia $3.9B AUM 50.88% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
First Manhattan
First Manhattan New York $39.2B AUM 21.04% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Pallas Capital Advisors's LUCD Position: Q2 2026 in Review

Pallas Capital Advisors opened a new position in Lucid Diagnostics (LUCD) in Q2 2026: 11,874 shares worth $12.7K. The stake represents ﹤0.01% of the portfolio and ranks #1023 among its holdings.

116 funds tracked by Wall St. Rank hold LUCD as of Q2 2026.

  • Pallas Capital Advisors held 11,874 shares of Lucid Diagnostics worth $12.7K as of Q2 2026.
  • Lucid Diagnostics was a new Pallas Capital Advisors position in Q2 2026.
  • Lucid Diagnostics made up ﹤0.01% of Pallas Capital Advisors's portfolio in Q2 2026, its #1023 holding.
  • 116 funds tracked by Wall St. Rank held Lucid Diagnostics as of Q2 2026.

Based on Pallas Capital Advisors's 13F filing for Q2 2026, filed 7 Aug 2026.